IQVIA Holdings Inc.
IQVNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 9/3013% above fair value
$245.82−4.73 (-1.89%)
Close on Nov 20, 2026Market cap $40.51BP/E 29.9Yield –
Iqvia Net Leverage Ratio by Quarter
Net Leverage Ratio (Net Debt / LTM Adjusted EBITDA) (×)
Iqvia Net Leverage Ratio: 3.45× in Q3 2026, down 2.0% from a year earlier.
Latest, Q3 2026
3.45
Period ended Sep 30, 2026
Change on a year earlier
-2.0%
3.52 in Q3 2025
History
40 quarters
Since Q4 2016
Sources
40
Documents cited below
Where the Q3 2026 figure comes from
“|| Net Leverage Ratio (Net Debt/LTM Adjusted EBITDA) | 3.45x”
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Iqvia Net Leverage Ratio (×), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Iqvia SEC filings and investor materials. https://stockdatahq.com/stocks/iqv/kpis/leverage-net-ratio
See every metric in the Iqvia KPI table. Data updated Nov 8, 2026.
See a number that looks wrong?